These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33796864)

  • 1. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.
    Oshima K; Zhao J; Pérez-Durán P; Brown JA; Patiño-Galindo JA; Chu T; Quinn A; Gunning T; Belver L; Ambesi-Impiombato A; Tosello V; Wang Z; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Balbin M; Nicolas C; Gastier-Foster JM; Devidas M; Loh ML; Paietta E; Tallman MS; Rowe JM; Litzow M; Minden MD; Meijerink J; Rabadan R; Ferrando A
    Nat Cancer; 2020 Nov; 1(11):1113-1127. PubMed ID: 33796864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
    Oshima K; Khiabanian H; da Silva-Almeida AC; Tzoneva G; Abate F; Ambesi-Impiombato A; Sanchez-Martin M; Carpenter Z; Penson A; Perez-Garcia A; Eckert C; Nicolas C; Balbin M; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Devidas M; Loh ML; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando AA
    Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11306-11311. PubMed ID: 27655895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
    Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Frey NV; Luger SM
    Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses.
    Szczepanek J; Styczyński J; Haus O; Tretyn A; Wysocki M
    Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):61-8. PubMed ID: 21246408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
    Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
    Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
    Ronson A; Tvito A; Rowe JM
    Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
    Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
    Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
    Dieck CL; Ferrando A
    Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
    Klumper E; Pieters R; Veerman AJ; Huismans DR; Loonen AH; Hählen K; Kaspers GJ; van Wering ER; Hartmann R; Henze G
    Blood; 1995 Nov; 86(10):3861-8. PubMed ID: 7579354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Hanif A; Wang ES; Thompson JE; Baron JI; Walsh MD; Griffiths EA
    Leuk Lymphoma; 2018 Aug; 59(8):2011-2013. PubMed ID: 29251203
    [No Abstract]   [Full Text] [Related]  

  • 16. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
    Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
    Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
    Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C
    Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
    Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
    Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
    Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
    Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
    Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
    Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.